Kling Bio and Sanofi Announce Strategic Collaboration to Accelerate Discovery of Neutralizing Antibodies

Biotech company Kling Bio today announced a research collaboration with global pharmaceutical leader Sanofi. The partnership aims to accelerate the discovery of potent neutralizing antibodies using Kling Bio’s proprietary Kling-Select platform, which leverages human B cell immortalization and functional screening.

Kling-Select is a clinically validated platform that enables the rapid identification of rare, immuno-functional antibodies and conserved viral epitopes, which are crucial for developing novel vaccines and therapeutics. Already successfully applied in RSV, COVID-19, and influenza, the technology screens directly from patient-derived B cells, bypassing the limitations of traditional, target-predefined discovery approaches.

“This collaboration highlights the transformative potential of our platform to address global health challenges by unlocking human-derived antibodies,” said Dr. Michael Koslowski, CEO of Kling Bio. “Together with Sanofi, we aim to advance the next generation of vaccines and therapeutics.”

Under the agreement, Sanofi will have an option to license selected results from the joint discovery work. Insights from the project are expected to not only fuel antiviral drug development but also provide a foundation for more effective vaccine design.